Fig. 4: Glucose-concentration-sensitive activation and deactivation of NNC2215 in vivo.
From: Glucose-sensitive insulin with attenuation of hypoglycaemia
a, Triggering of NNC2215 by dosing rats i.v. with 0 to 2 g kg–1 l-glucose, resulting in lowering of d-glucose. Data are mean ± s.e.m. n = 7 animals per group. b, Glucose dose-dependent clearance of NNC2215 measured by the NNC2215 concentration at 60 min. Data are mean ± s.e.m. n = 7 animals per group. Statistical analysis was performed using a two-sided Student’s t-test; *P = 0.013. c, Representative glucose profiles in LYD pigs during constant i.v. infusion of NNC2215 (1.86 pmol kg−1 min−1) or insulin degludec (0.9 pmol kg−1 min−1) after stopping and restarting the constant i.v. glucose infusion (6 mg kg−1 min−1). Data are mean ± s.d. n = 7 (NNC2215) and n = 8 (insulin degludec) pigs. d, Pharmacokinetic/pharmacodynamic modelling results for a representative LYD pig dosed with 1.72 pmol kg−1 min−1 NNC2215. SI, insulin sensitivity index.
